Hudson Bay Capital Management’s Recursion Pharmaceuticals RXRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $759K | Buy |
150,000
+22,930
| +18% | +$116K | ﹤0.01% | 687 |
|
|
2025
Q1 | $672K | Buy |
127,070
+49,570
| +64% | +$262K | ﹤0.01% | 633 |
|
|
2024
Q4 | $524K | Sell |
77,500
-12,500
| -14% | -$84.5K | ﹤0.01% | 597 |
|
|
2024
Q3 | $593K | Buy |
90,000
+45,000
| +100% | +$297K | ﹤0.01% | 520 |
|
|
2024
Q2 | $338K | Buy |
45,000
+15,000
| +50% | +$113K | ﹤0.01% | 534 |
|
|
2024
Q1 | $299K | Sell |
30,000
-50,000
| -63% | -$499K | ﹤0.01% | 500 |
|
|
2023
Q4 | $789K | Buy |
80,000
+40,000
| +100% | +$394K | 0.01% | 460 |
|
|
2023
Q3 | $306K | Sell |
40,000
-70,000
| -64% | -$536K | ﹤0.01% | 530 |
|
|
2023
Q2 | $822K | Buy |
+110,000
| New | +$822K | 0.01% | 540 |
|
|
2022
Q3 | – | Sell |
-120,000
| Closed | -$977K | – | 1289 |
|
|
2022
Q2 | $977K | Sell |
120,000
-80,000
| -40% | -$651K | 0.01% | 893 |
|
|
2022
Q1 | $1.43M | Buy |
+200,000
| New | +$1.43M | 0.02% | 763 |
|